Business
Data for peanut allergy vaccine published in JACI
Data for peanut allergy vaccine published in JACI.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 3044B Allergy Therapeutics PLC 29 January 2020 \n\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\nAllergy Therapeutics publishes encouraging new data for peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology \n- Positive preclinical data package demonstrates positive safety and efficacy profile reducing systemic and local allergic symptoms in a peanut allergy model\n \n- Manufacturing scale-up for clinical studies to evaluate allergy vaccination using VLP (virus like particle) technology underway\n\n29 January 2020 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces publication of positive preclinical results of its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology (JACI). \n \nThe study, which introduces the principles of vaccination into the allergy field, used a peanut allergy mouse model to demonstrate that the novel virus like particle (VLP) platform used in the vaccine candidate could offer an effective way to treat peanut allergies and prevent anaphylaxis. It provides the proof of concept for the generation of sustained immunity and protection through vaccination. The study illustrated that a single injection protected against systemic anaphylaxis, as demonstrated via subsequent in vivo challenge, skin prick testing and oral challenge. \n \nThere are currently no approved immunotherapies for the treatment of, or to cure, patients suffering from peanut allergy, which remains a frequent cause of anaphylactic reactions among food allergies. Prevalence of peanut allergy in Western countries ranges from 1.4-3% of children1, with UK figures estimating around 2% of children in the UK are affected2. In the US, peanut allergy affects an estimated 1.2% of the overall US population3 and 1 in 4 children with a peanut allergy ...